postpartum depression

View All

Mixed Fortunes for Biogen and Sage’ Zuranolone: Approval Under the Cloud of Rejection

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...

Find More

Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More

Pharma News for CG Oncology, Amgen, Elevar, and GSK
CG Oncology Teams Up With Merck & BMS; Parse Biosciences Partners With Molecular Diagnostics Korea; Amgen’s Olpasiran; Elevar Therapeutics Announces Results of Rivoceranib; FDA Approves GSK’s Measles Vaccine; Sage & Biogen Reveals Postpartum Depression Trial Result

FDA Gives Green Signal to First Measles Vaccine in Almost 50 Years GSK announced that the company's vaccine for protection against mumps, measles, and rubella (MMR) had been approved by the U.S. FDA. According to data from six clinical studies, the company filed a Biologics License Application in August 2021. ...

Find More

How Depression Is Eroding The Mental And The Physical Health Of The Society?

Depression is a global health burden and continues to increase with each passing day. As per the WHO, globally, more than 264 million people of all ages suffer from depression. It is one of the leading causes of disability as measured by Years Lived with Disability (YLDs) and the fourth leading contributor to disea...

Find More

artificial intelligence
The Business Cocktail

Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the cli...

Find More

Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod

The oral depression drug of Sage Therapeutics meets phase 3 efficacy A phase 3 trial of oral treatment of Sage Therapeutics for postpartum depression (PPD) has hit its primary endpoint. The drug, SAGE-217, showed significant improvements on a depression score and saw no fainting cases. SAGE-217 is an a...

Find More